T1D Closed-loop and Physical Activity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-05-06

Study Completion Date

2026-05-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

"Physical activity is recognized as beneficial for patients living with type 1 diabetes (T1DM), with a demonstrated effect not only on HbA1c control \[1\] but also on reducing the incidence of diabetes-related complications \[2,3\]. It is recommended that patients living with T1DM perform 150 minutes of accumulated physical activity per week, without exceeding two consecutive days without physical activity \[4\]. Indeed, one meta-analysis reported that moderately vigorous activity (≥4.5 METs) was beneficial compared with lower-intensity activity, while three other studies noted that only vigorous physical activity (≥6 METs) predicted lower all-cause mortality rates \[5\]. However, T1DM can represent a major obstacle to physical activity because of the occurrence of fairly frequent hypoglycemia, including after physical effort, the need for early resugaring but also the risk of hyperglycemia (rebound or with certain activities) \[6\]. The advent of automated insulin delivery systems has led to a significant improvement in time on target and a reduction in the frequency of hypoglycemia, including during physical activity in some studies \[7-9\]. The aim of this study is therefore to evaluate, in a cohort of patients with T1DM, whether the implementation of a closed-loop automated insulin delivery system increases physical activity in patients with T1DM. Based on the interpretation of the ONAPS-PAQ \[10\], the investigator hypothesize that the implementation of the closed-loop system enables an individual to reach the 3000 MET/min/week threshold (considered ""Active+"" from this threshold onwards).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT06967701

Type 1 Diabetes (T1D) Latent Autoimmune Diabetes in Adult (LADA) Pancreatitis

RECRUITING NA

Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes

NCT06098729

Type 1 Diabetes Latent Autoimmune Diabetes in Adults Pancreatitis

COMPLETED NA

24-hour Movement Behaviors in Adults With Type 1 Diabetes

NCT06425640

Diabetes Mellitus, Type 1

RECRUITING

Virtual Physical Activity for Type 1 Diabetes

NCT05163912

Type 1 Diabetes

COMPLETED NA

HIT on Hypoglycemic Risk in Type 1 Diabetes (T1D)

NCT03598400

Type1diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes type1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Type 1 diabetes with insulin infusion system

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Type 1 diabetes with insulin infusion system

No intervention

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

No intervention

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 1 diabetes defined by clinical history and positive measurement of autoantibodies (anti-GAD or IA2), evolving for more than 6 months and treated by insulin pump for at least 6 months, for whom an indication for automated insulin delivery is retained, by criteria of glycemic control (HbA1c ≥ 8% and/or significant glycemic variability and/or severe hypoglycemia) or poor quality of life, in accordance with reimbursement criteria validated by the CNAM for available systems.
* For women, existence of effective contraception (hormonal or mechanical) and no plans for pregnancy during the study period.
* Having a Health Care insurance."" "

Exclusion Criteria

* Patient already involved in another experimental study
* Patient in a particular situation deemed incompatible with the study by the investigator
* Patient living in a department other than Alpes-Maritimes or Var
* Pregnant women
* Presence of a contraindication to physical activity
* Patient with linguistic or psychological incapacity to understand written information
* Patient refusing to give consent
* Patient deprived of liberty by administrative or judicial decision, under guardianship or trusteeship"" "

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No